Cargando…
Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
A feasibility study was performed to evaluate the immunological efficacy and safety of a personalized peptide vaccine (PPV) for cervical cancer patients who have received platinum-based chemotherapy. A total of 24 patients with standard chemotherapy-resistant cervical cancer, including 18 recurrent...
Autores principales: | Kawano, Kouichiro, Tsuda, Naotake, Waki, Kayoko, Matsueda, Satoko, Hata, Yoshiro, Ushijima, Kimio, Itoh, Kyogo, Yamada, Akira, Kamura, Toshiharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582979/ https://www.ncbi.nlm.nih.gov/pubmed/26122553 http://dx.doi.org/10.1111/cas.12729 |
Ejemplares similares
-
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
por: Waki, Kayoko, et al.
Publicado: (2017) -
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012) -
Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
por: Ushijima, Kimio, et al.
Publicado: (2013) -
Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device
por: Tsuda, Naotake, et al.
Publicado: (2014) -
CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)